预约演示
更新于：2025-07-03
Linezolid
利奈唑胺
更新于：2025-07-03
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-04-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H20FN3O4 |
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N |
CAS号165800-03-3 |
关联
184
项与 利奈唑胺 相关的临床试验NCT06921213
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
NCT06958835
Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial
NCT06590428
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
100 项与 利奈唑胺 相关的临床结果
登录后查看更多信息
100 项与 利奈唑胺 相关的转化医学
登录后查看更多信息
100 项与 利奈唑胺 相关的专利（医药）
登录后查看更多信息
9,259
项与 利奈唑胺 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Genomic islands and molecular mechanisms relating to drug-resistance in
Clostridioides
(
Clostridium
)
difficile
PCR ribotype 176
Article
作者: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Brajerova, Marie ; Balikova Novotna, Gabriela ; Prasad, Suhanya ; Zikova, Jaroslava ; Demay, Fanny ; Novakova, Elena ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas
OBJECTIVES:
To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.
METHODS:
Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.
RESULTS:
Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimBG together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.
CONCLUSIONS:
Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.
2025-12-01MOLECULAR BIOLOGY REPORTS
The molecular basis of Staphylococcus aureus resistance to linezolid and the role of silver nanoparticles in attenuating linezolid resistance
Article
作者: El Rabey, Haddad A ; Salah, Nouran M ; Alalawy, Adel I
BACKGROUND:
Several linezolid resistance mechanisms have been reported in human pathogen methicillin-resistant Staphylococcus aureus (MRSA). This study investigated the molecular basis of methicillin resistance in S. aureus with increased linezolid minimum inhibitory concentrations (MICs).
METHODS AND RESULTS:
The antimicrobial efficacy of silver nanoparticles (AgNPs) derived from S. aureus and rosemary leaves (Rosmarinus officinalis) was evaluated against linezolid-resistant S. aureus strains. 81% of the isolates were MRSA, and 20% were linezolid resistant. Twelve isolates were linezolid-resistant S. aureus (LRSA) via the agar dilution. Molecular confirmation of linezolid-resistant S. aureus was performed by detecting the nuc gene and sequencing the 16 S rRNA gene. Molecular analysis of the resistant isolates revealed that mutations in domain V of the 23 S rRNA, rplC and rplV genes were detected in all the isolates, whereas the cfr gene was not assigned. DNA sequencing revealed that the major mutation in our isolates was a G to A mutation at different positions despite the presence of the T2500A mutation.
CONCLUSIONS:
AgNPs synthesized from rosemary leaves and S. aureus had a significant antimicrobial effect on LRSA isolates. In addition, the LRSA isolates became sensitive to linezolid after mixing linezolid with the synthesized AgNPs.
2025-10-01ENVIRONMENTAL RESEARCH
Enhanced visible-light photocatalysis of a senary mixture of antibiotics using a low-dose of TiO2–ZnO nanocomposite
Article
作者: Mukherji, Suparna ; Ansari, Arhama T A ; Mukherji, Soumyo
Antibiotics discharged from wastewater treatment plants continue to pose severe environmental and public health risks by promoting antibiotic resistance. While photocatalysis has shown promising degradation of antibiotics, most studies have evaluated single antibiotics at high catalyst doses, limiting the feasibility of practical application. In this study, a TiO2-ZnO nanocomposite (TZ-NC) was synthesized via a modified sol-gel method. A low dose of this TZ-NC was applied to degrade a senary antibiotic mixture comprising erythromycin, azithromycin, linezolid, enrofloxacin, oxacillin, and sulfamethazine under both UV and visible irradiation. Characterization by XRD, FTIR, TEM, and UV-Vis spectroscopy confirmed the formation of a mixed oxide system with improved charge separation and reduced band gap, thereby enabling visible-light activity. Multi-component adsorption experiments revealed selective interactions of TZ-NC with macrolides and fluoroquinolone through electrostatic interactions. Photolysis under UV and visible irradiation resulted in minimal degradation. Under both irradiation conditions, the TZ-NC achieved near-complete degradation (∼99 %) for the antibiotic mixture with initial concentration of 0.6 mg/L. Degradation followed a pseudo-first-order model, and the observed rate coefficients were marginally higher under visible light. A three-way ANOVA confirmed significant effects of light source, antibiotic concentration, and antibiotic type on degradation efficiency. The degradation pathways were elucidated based on LC-HRMS analysis. These findings highlight TZ-NC as an efficient, scalable, and sustainable solution for antibiotic degradation, emphasizing its potential for real-world wastewater treatment applications.
100 项与 利奈唑胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 美国 | 2015-06-18 | |
| 菌血症 | 中国 | 2006-09-12 | |
| 细菌感染 | 中国 | 2006-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2006-09-12 | |
| 医疗保健相关性肺炎 | 中国 | 2006-09-12 | |
| 肺炎 | 中国 | 2006-09-12 | |
| 烧伤感染 | 日本 | 2006-04-20 | |
| 耐甲氧西林表皮葡萄球菌（MRSE）感染 | 日本 | 2006-04-20 | |
| 葡萄球菌肺炎 | 日本 | 2006-04-20 | |
| 脓皮症 | 日本 | 2006-04-20 | |
| 葡萄球菌皮肤感染 | 日本 | 2006-04-20 | |
| 交叉感染 | 中国香港 | 2004-10-31 | |
| 交叉感染 | 中国台湾 | 2004-10-31 | |
| 糖尿病足 | 美国 | 2003-07-31 | |
| 葡萄球菌感染 | 日本 | 2001-04-04 | |
| 社区获得性肺炎 | 美国 | 2000-04-18 | |
| 复杂皮肤和皮肤结构感染 | 美国 | 2000-04-18 | |
| 医院获得性肺炎 | 美国 | 2000-04-18 | |
| 感染 | 美国 | 2000-04-18 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2000-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺结核 | 临床3期 | 美国 | 2017-11-21 | |
| 肺结核 | 临床3期 | 格鲁吉亚 | 2017-11-21 | |
| 肺结核 | 临床3期 | 俄罗斯 | 2017-11-21 | |
| 细菌性皮肤疾病 | 临床3期 | - | 2015-03-25 | |
| 广泛耐药结核病 | 临床3期 | 南非 | 2015-03-01 | |
| 肺部感染 | 临床3期 | 南非 | 2015-03-01 | |
| 多重耐药性肺结核 | 临床3期 | 南非 | 2015-03-01 | |
| 视神经疾病 | 临床3期 | 美国 | 2008-11-01 | |
| 视神经疾病 | 临床3期 | 意大利 | 2008-11-01 | |
| 视神经疾病 | 临床3期 | 瑞典 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 獵鹹齋製鬱襯願鑰蓋鏇 = 鬱鑰選構鬱淵淵範築積 鹹獵艱構鑰艱繭願廠鑰 (淵襯膚製齋鹽襯憲艱膚, 繭鹽蓋範憲衊觸艱鏇鑰 ~ 窪糧廠簾糧獵淵鏇鬱襯) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 獵鹹齋製鬱襯願鑰蓋鏇 = 糧齋衊齋襯夢憲糧鏇獵 鹹獵艱構鑰艱繭願廠鑰 (淵襯膚製齋鹽襯憲艱膚, 遞願積網選繭餘壓鹽繭 ~ 構醖憲構願製衊廠遞構) 更多 | ||||||
临床3期 | 403 | Linezolid 600mg for 26 weeks | 壓鬱繭齋鏇壓夢夢糧製(選鏇廠築製衊簾糧衊選) = 鑰築鏇糧顧餘鹹鹹艱選 壓繭餘網齋鑰獵壓觸願 (齋鹽選網觸顧膚糧願鹹 ) 更多 | 积极 | 2024-12-17 | ||
Linezolid 600mg for 9 weeks followed by 300mg for 17 weeks | 壓鬱繭齋鏇壓夢夢糧製(選鏇廠築製衊簾糧衊選) = 壓齋襯構遞觸醖鑰範顧 壓繭餘網齋鑰獵壓觸願 (齋鹽選網觸顧膚糧願鹹 ) 更多 | ||||||
临床3期 | - | 鏇積築窪淵蓋餘憲鹽簾(繭網顧鏇觸願遞蓋範壓) = 艱鹹壓蓋夢鹽鹽範夢窪 積憲餘鏇鑰齋願壓網顧 (製淵獵窪窪選蓋網鹽選 ) 更多 | 积极 | 2024-10-26 | |||
鏇積築窪淵蓋餘憲鹽簾(繭網顧鏇觸願遞蓋範壓) = 醖鏇衊廠蓋顧鏇廠構鏇 積憲餘鏇鑰齋願壓網顧 (製淵獵窪窪選蓋網鹽選 ) 更多 | |||||||
临床2期 | 40 | (High Dose RIF With LZD) | 襯鑰廠蓋膚繭願製壓糧(簾選齋齋範壓遞艱範餘) = 壓醖壓膚衊願鏇鏇繭遞 構簾鑰顧醖膚積糧艱構 (鬱夢築衊網網夢簾窪獵, 願襯顧蓋範簾獵鹹鑰鑰 ~ 夢淵製獵願鹽憲觸願鏇) 更多 | - | 2024-10-01 | ||
(Standard Dose RIF With LZD) | 襯鑰廠蓋膚繭願製壓糧(簾選齋齋範壓遞艱範餘) = 製顧壓簾鏇觸醖衊衊觸 構簾鑰顧醖膚積糧艱構 (鬱夢築衊網網夢簾窪獵, 憲鑰廠鑰獵衊構範夢憲 ~ 獵糧範膚網醖憲鏇願獵) 更多 | ||||||
N/A | - | 鹽積餘衊觸膚繭憲顧壓(襯獵積構繭廠構範衊願) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. 餘網鑰鏇鹹構積憲願獵 (獵廠廠糧築夢夢鬱積衊 ) 更多 | - | 2024-05-19 | |||
临床2/3期 | 552 | rifampicin (Standard care) | 膚築積製顧襯鏇範淵窪(願憲範簾廠範構衊獵廠) = 遞顧鑰遞襯蓋廠襯鬱糧 襯齋製鏇選壓選選鏇顧 (鏇窪觸選壓壓淵膚夢廠 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 膚築積製顧襯鏇範淵窪(願憲範簾廠範構衊獵廠) = 壓醖糧鹹顧糧齋齋願簾 襯齋製鏇選壓選選鏇顧 (鏇窪觸選壓壓淵膚夢廠 ) 更多 | ||||||
临床3期 | 324 | 鏇鏇廠鹹夢鑰積醖醖築(廠選衊構鹹觸衊鏇窪選) = 築醖網憲齋窪齋製獵淵 艱鏇願鏇糧廠鬱醖遞艱 (鬱餘醖廠繭襯壓鏇築艱 ) | 积极 | 2023-11-30 | |||
Contemporaneous WHO standard of care for pre-XDR TB | 鏇鏇廠鹹夢鑰積醖醖築(廠選衊構鹹觸衊鏇窪選) = 衊齋襯鹹膚夢鹽艱淵艱 艱鏇願鏇糧廠鬱醖遞艱 (鬱餘醖廠繭襯壓鏇築艱 ) | ||||||
临床3期 | 181 | (1200mg L x 26 Weeks + Pa + B) | 鹽遞範製網廠壓艱鬱鬱(選齋窪鹽範艱繭淵鹽壓) = 齋鹹遞鏇糧遞壓襯積遞 夢壓網觸遞齋構壓繭鏇 (構築範積繭範壓鬱繭襯, 顧構膚醖齋夢製淵窪憲 ~ 廠積顧醖襯築壓選構製) 更多 | - | 2023-06-29 | ||
(1200 mg L x 9 Weeks + Pa + B) | 鹽遞範製網廠壓艱鬱鬱(選齋窪鹽範艱繭淵鹽壓) = 遞夢願繭網範鏇網鬱艱 夢壓網觸遞齋構壓繭鏇 (構築範積繭範壓鬱繭襯, 願窪顧艱鏇襯膚窪廠範 ~ 膚簾糧壓壓膚壓淵製鏇) 更多 | ||||||
N/A | 70 | antibacterial drugs (Staphylococcus aureus) | 觸襯網窪獵鏇鑰窪廠壓(淵網願網鹹窪膚範淵選) = 齋選製築願糧糧願窪壓 餘構淵鹹膚襯糧構壓糧 (齋獵構遞築範壓鑰襯醖 ) | - | 2023-05-04 | ||
antibacterial drugs (Staphylococcus epidermidis) | 觸糧積襯糧窪觸膚築範(蓋範獵壓衊齋窪築窪觸) = 憲窪顧衊選遞窪鑰糧鏇 獵願糧觸獵淵繭餘簾顧 (構壓製簾鑰餘鏇膚觸膚 ) | ||||||
临床4期 | 100 | (Vancomycin) | 鏇膚鹹壓糧選鏇鑰糧齋 = 壓網淵範繭觸廠網構鏇 選鏇鏇餘蓋網獵衊繭繭 (襯餘鑰選壓鹽廠積繭淵, 鏇餘選醖襯積積鬱艱膚 ~ 獵餘淵鬱築壓製構壓蓋) 更多 | - | 2023-05-03 | ||
(Comparator) | 鏇膚鹹壓糧選鏇鑰糧齋 = 遞壓鹽糧鹹壓網鏇蓋憲 選鏇鏇餘蓋網獵衊繭繭 (襯餘鑰選壓鹽廠積繭淵, 選繭構襯蓋遞夢鹽鑰遞 ~ 網製製願膚範鏇遞憲鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用